Navigation Links
InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
Date:2/7/2008

PF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 within the Roche research and development programs) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated future financial results and product development. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 30, 2007 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) the risk that physician prescriptions of Actimmune for the treatment of IPF, an indication for which Actimmune has not been approved by the FDA, have dec
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... have received a $451,781 Air Force Office of Scientific ... micro- and nano-scale level that will provide clues for ... Mechanical and Aerospace Engineering, said the new technology and ... X-rays of an aircraft,s wing., "We,ll be able to ... look at it on this scale," Huang said. "Certain ...
(Date:10/17/2014)... and HILDEN, Germany ...   , Translational research in cancer ... being presented at the American Society of Human ... 250,000-plus DNA samples linked to Ingenuity ®  Knowledge ... for genomic analysis  Ingenuity ®  Variant ...
(Date:10/17/2014)... 17, 2014 Bioquell, provider of ... by health facilities around the world to decontaminate ... treated. Among the many places the hydrogen peroxide ... Presbyterian Hospital Dallas and at the National Institutes ... robots have been utilized to decontaminate patient rooms, ...
(Date:10/17/2014)... 2014 The global SWIR market report ... and forecast of revenue. This market is valued at ... $97.9 million by 2019, at a CAGR of 10.2% ... of the global SWIR market report, to get an ... a glimpse of the segmentation of the market, and ...
Breaking Biology Technology:UT Arlington project to detect possible damages in aircraft parts early in process 2QIAGEN Demonstrates Expanded Bioinformatics Workflows at ASHG; Strong Market Adoption as Researchers Analyze Genomic Data on More Than a Quarter-Million Samples in Secure Private Cloud 2QIAGEN Demonstrates Expanded Bioinformatics Workflows at ASHG; Strong Market Adoption as Researchers Analyze Genomic Data on More Than a Quarter-Million Samples in Secure Private Cloud 3QIAGEN Demonstrates Expanded Bioinformatics Workflows at ASHG; Strong Market Adoption as Researchers Analyze Genomic Data on More Than a Quarter-Million Samples in Secure Private Cloud 4QIAGEN Demonstrates Expanded Bioinformatics Workflows at ASHG; Strong Market Adoption as Researchers Analyze Genomic Data on More Than a Quarter-Million Samples in Secure Private Cloud 5QIAGEN Demonstrates Expanded Bioinformatics Workflows at ASHG; Strong Market Adoption as Researchers Analyze Genomic Data on More Than a Quarter-Million Samples in Secure Private Cloud 6Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 2Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 3Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 4Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 5Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 6The global SWIR market is expected to reach $97.9 million by 2019 - New Report by MicroMarket Monitor 2The global SWIR market is expected to reach $97.9 million by 2019 - New Report by MicroMarket Monitor 3
... 29, 2011 Texas Children,s Hospital in Houston announced today ... States to implant an artificial heart into the chest of ... life. The history-making patient underwent a rare 15-hour operation on ... He is one of three congenital heart patients in the ...
... 2011 UCB and Harvard University will officially launch ... to take place in Boston in the presence of ... The Alliance creates a unique drug discovery bridge between ... that holds potential for the development of new therapeutic ...
... (Nasdaq: VRNM ), a leading industrial biotechnology company ... announced the signing of a lease agreement for new office ... Diego, CA.  The lease is targeted to commence in the ... facility and the expiration of Verenium,s current sublease, which was ...
Cached Biology Technology:Texas Children's Hospital is First Pediatric Hospital in the Nation to Implant Artificial Heart 2Texas Children's Hospital is First Pediatric Hospital in the Nation to Implant Artificial Heart 3Texas Children's Hospital is First Pediatric Hospital in the Nation to Implant Artificial Heart 4Texas Children's Hospital is First Pediatric Hospital in the Nation to Implant Artificial Heart 5UCB to Launch Research Alliance With Harvard University 2UCB to Launch Research Alliance With Harvard University 3Verenium Announces Signing of Lease for New Office and Lab Space 2Verenium Announces Signing of Lease for New Office and Lab Space 3
(Date:10/15/2014)... awarded the 44th Rosenstiel Award for Distinguished Work in ... exploring the mechanisms of genomic instability and its implications ... the second alumnus to win the Rosenstiel Award; the ... , Alt is the Charles A. Janeway Professor of ... and an investigator at the Howard Hughes Medical Institute ...
(Date:10/14/2014)... DURHAM, N.C. – Like discriminating thieves, prostate cancer tumors ... in the body. But such avarice may be a ... found a way to kill prostate cancer cells by ... that selectively destroys the diseased cells brimming with the ... which uses two drugs already commercially available for other ...
(Date:10/14/2014)... Ohio (Oct. 14, 2014)—It,s been millions of years since ... a team led by Ohio University scientists is breathing ... model airflow through dinosaur snouts. The research has important ... only breathe but to enhance the sense of smell ... ,nosy, animals," said Ohio University doctoral student Jason Bourke, ...
Breaking Biology News(10 mins):Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Prostate cancer's penchant for copper may be a fatal flaw 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3
... of the Eastern Illinois Foodbank shared results of a ... domestic hunger-relief organization. The study is completed every four ... effectiveness of emergency food distribution throughout the United States. ... Agricultural and Consumer Economics at the University of Illinois, ...
... homosexuality doesn,t make complete sense from an evolutionary point ... but because homosexual men are much less likely to ... this trait have been extinguished long ago? What value ... for eons even without any discernible reproductive advantage? ...
... at Washington University in St. Louis sheds light on one ... land by plants 480 million years ago. No would-be ... to deal with dehydration, a major threat for organisms accustomed ... land plants managed to avoid drying out might be provided ...
Cached Biology News:U of I faculty assist in evaluating US food security programs 2Study reveals potential evolutionary role for same-sex attraction 2Study reveals potential evolutionary role for same-sex attraction 3Moss helps chart the conquest of land by plants 2Moss helps chart the conquest of land by plants 3Moss helps chart the conquest of land by plants 4
...
Ultra-sensitive, non-radioactive detection of rat Osteopontin...
Agarose-LE, 250 g. Suitable for soft agarose cloning. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1200 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Request Info...
Biology Products: